GLP-1 Daily: Ozempic & Wegovy News
Houston Pharmacy Recalls Compounded Tirzepatide After FDA Sterility Findings; Belgium Warns on Off-Label Use
Wednesday, October 21, 2026 · 7 min
An FDA inspection report details 14 problems at Houston RX, the pharmacy behind a nationwide recall of compounded tirzepatide vials, while Belgium's medicines agency warns against off-label GLP-1 use and black-market retatrutide. Plus, Novo's company-reported CagriSema data in women ahead of an expected FDA decision.
Listen
Show notes
An FDA inspection report details 14 problems at Houston RX, the pharmacy behind a nationwide recall of compounded tirzepatide vials, while Belgium's medicines agency warns against off-label GLP-1 use and black-market retatrutide. Plus, Novo's company-reported CagriSema data in women ahead of an expected FDA decision.
In this episode
- Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients — Medical Daily
“Inspectors also wrote that on August 3 the pharmacy recovered microbial growth in the ISO 5 hood after filling a lot of tirzepatide-niacinamide. No investigation followed because the firm's action level was not appropriate, according to the FDA, and that lot was released and…”
- GLP-1 analogues and GIP/GLP-1 dual analogues: risks associated with misuse and off-label use for weight loss | FAMHP — FAMHP
“In practice: for weight loss in people who are neither obese nor demonstrably overweight – and where this is not associated with health problems – the risks associated with treatment may outweigh the potential benefits.”
- CagriSema Weight Loss in Women | Novo Nordisk U.S. — Novo Nordisk U.S.
“CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.”